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INTRODUCTION
Endometrial cancer (EC) is the most frequently 
observed invasive tumor of the female genital tract and 
the fourth most common cancer in women in developed 
countries, accounting for 60,050 diagnosed cases and 
10,470 estimated deaths in 2016 in the United States [1]. 
Postmenopausal women represent 86% of diagnosed EC 
cases, with a median age of 63 years [2]. Nowadays, 70% 
of the EC cases are diagnosed at early stages of the disease 
where the tumor is still localized within the endometrium 
and is associated with an overall 5-year survival rate of 
96%. However, 30% of EC patients are diagnosed at an 
advanced stage of the disease associated with a drastic 
decrease in the 5-year survival rate, which is reduced 
to 68% when myometrial invasion and/or lymph node 
affectation is already present, and to 17% in cases of 
distant metastasis [1]. Improving early diagnosis is hence 
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ABSTRACT
About 30% of endometrial cancer (EC) patients are diagnosed at an advanced 
stage of the disease, which is associated with a drastic decrease in the 5-year survival 
rate. The identification of biomarkers in uterine aspirate samples, which are collected 
by a minimally invasive procedure, would improve early diagnosis of EC. We present a 
sequential workflow to select from a list of potential EC biomarkers, those which are 
the most promising to enter a validation study. After the elimination of confounding 
contributions by residual blood proteins, 52 potential biomarkers were analyzed in 
uterine aspirates from 20 EC patients and 18 non-EC controls by a high-resolution 
accurate mass spectrometer operated in parallel reaction monitoring mode. The 
differential abundance of 26 biomarkers was observed, and among them ten proteins 
showed a high sensitivity and specificity (AUC > 0.9). The study demonstrates that 
uterine aspirates are valuable samples for EC protein biomarkers screening. It also 
illustrates the importance of a biomarker verification phase to fill the gap between 
discovery and validation studies and highlights the benefits of high resolution mass 
spectrometry for this purpose. The proteins verified in this study have an increased 
likelihood to become a clinical assay after a subsequent validation phase.
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a major issue to appropriately manage EC and decrease 
mortality associated with the disease. 
Early detection of EC patients is favored by the 
presence of symptoms like abnormal vaginal bleeding, 
present in 93% of women diagnosed with EC. However, 
many other benign disorders generate similar symptoms 
[3]. Discrimination of patients with benign endometrial 
pathologies and with EC is only achieved after a tedious 
diagnostic process consisting of a pelvic examination and 
a transvaginal ultrasonography followed by a confirmatory 
histopathological examination of an endometrial biopsy. 
The preferable biopsy used in this procedure is named 
uterine aspirate or pipelle biopsy and is obtained by a 
minimally invasive aspiration of endometrial fluid from 
inside the uterine cavity using a Cornier pipelle. Using 
this sampling, this process has unfortunately a diagnostic 
failure and an inadequate sampling rate of 8% and 15%, 
respectively; which is increased in postmenopausal women 
up to 12% and 22% [4]. In those undiagnosed cases, a 
biopsy guided by hysteroscopy needs to be performed, 
but this invasive technique presents more complications, 
including uterine perforation, hemorrhage and possible 
damage to other organs [5]. Implementation of biomarkers 
in early stages of the diagnostic process would improve 
detection of EC. 
From a biological point of view, proteins are key 
players of many cellular processes and variations of their 
abundance can be associated with pathologies such as 
cancer. Proteins are detectable in biofluids and thus are 
valuable disease indicators for the development of non-
invasive diagnostic tests. In this regard, uterine aspirates are 
specially promising as a source of EC biomarkers thanks 
to the direct contact of this fluid with the endometrium. 
Nevertheless, the search of protein EC biomarkers has 
been mostly based on tissue analyses [6–8], hampering the 
translation into clinical practice. Only few proteomic studies 
have been performed on uterine aspirates without a focus on 
EC biomarkers [9–11]. 
The ideal diagnostic biomarker pipeline consists of 
sequential phases of discovery, verification and validation. 
The discovery produces large lists of differentially 
abundant proteins (i.e. 100 s–1000 s) between simplified 
biological conditions using a limited number of samples, 
mostly tissue specimens. In contrast, the validation phase 
requires a precise and accurate quantification of the most 
promising biomarker candidates (typically a dozen), in a 
large set of samples, which is normally a preferred biofluid 
[12]. Up to date in EC, the vast majority of biomarker 
studies cover either discovery phases that generates large 
lists of biomarker candidates [13, 14], most of which have 
never been further validated; or validation studies focus 
on a specific protein [15–18], with an increased risk of not 
generating concrete application and hampering the search of 
biomarker panels that improve the diagnostic performance 
of individual proteins. The intermediate verification phase 
is crucial for the prioritization of biomarker candidates to 
enter a validation phase in order to increase the likelihood 
of identifying clinically relevant biomarkers [19]. The lack 
of methods to guide the prioritization of candidates in the 
verification phase has been identified as one of the factors 
of poor translation of biomarker discovery into clinics 
[20, 21]. The liquid chromatography mass spectrometry 
(LC-MS) platform, operated in targeted acquisition mode, 
is ideal to achieve this task as proteins can be reliably 
quantified in a highly multiplexed fashion and at a fast 
throughput.
In this study we aimed to i) demonstrate the 
efficiency of a stepwise verification workflow that 
prioritizes, from a list of potential biomarkers derived 
from published discovery studies, the most promising 
to enter into a further validation phase; ii) evaluate the 
performance of the parallel reaction monitoring (PRM), a 
targeted acquisition method employed on a high resolution 
accurate mass spectrometer, in clinical samples of uterine 
aspirates; and iii) assess the potential of the soluble 
fraction of uterine aspirates as a source of protein EC 
biomarkers.
RESULTS 
LC-PRM method development: Selection of the 
biomarker candidates
A targeted MS-based approach was selected for the 
verification of potential EC biomarkers in uterine aspirates 
as it enables the quantification of multiple peptides within 
a single analysis. The LC-PRM is a hypothesis driven 
methodology that differs from the unsupervised MS-based 
approaches (e.g. data dependent and data independent 
acquisition) as the proteins must be selected prior the 
actual MS acquisition. With LC-PRM, the number of 
targets is limited to approximately 100–150 peptides per 
analysis, but in return, the mass accuracy and the high 
resolving power of the orbitrap analyzer, in conjunction 
with the use of isotope labeled peptides as internal 
standard, allows for systematic quantitative measurements 
in all samples achieved with a high degree of selectivity 
and precision. Therefore, a preselection of the protein 
candidates to be measured is required. Starting from 506 
protein candidates found in the literature from previous 
studies mainly using EC tissue samples as biological 
material, we proposed a workflow to reduce step by step 
this number down to 52 biomarker candidates, leading to 
98 pairs of light/heavy peptides that can be measured by a 
single LC-PRM method. We verified those candidates in 
uterine aspirates from a cohort of 20 EC patients and 18 
controls by LC-PRM (Figure 1).
The first step of this study was to select proteins 
indicated as potential biomarkers for EC from an extensive 
literature review performed in the PUBMED bibliographic 
database. The search included articles published from 
1990 to 2014, combined with the text words“endometrial 
cancer” and “biomarker”. We obtained a first list of 506 
proteins associated with EC, which were mostly derived 
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from studies performed in endometrial tissue samples. The 
second step of selection consisted in the assessment of the 
LC-MS detectability of those 506 potential biomarkers 
in four samples of uterine aspirates by repeated DDA 
analysis. The main goal of this step was to reduce the list 
of protein candidates initially described in tissue samples 
to those that can be effectively detected in uterine aspirate 
samples. From a total of 1,086 proteins identified in the 
four uterine aspirates, 158 proteins out of the initial 506 
potential biomarkers list were detected (Supplementary 
Table 1). This first screening indicated that one third of the 
potential biomarkers could be easily detected by LC-MS 
techniques in uterine aspirates samples, thus confirming 
the potential of uterine aspirates as a source of protein EC 
biomarkers.
Blood contamination of biological samples is a 
recurrent problem in bioanalyses, particularly in the 
field of biomarker research in some biofluids [22, 23]. 
Understanding that uterine aspirates display a variable 
amount of blood between samples, we introduced a 
third step of selection to evaluate the interference of 
blood components during LC-MS detection of the 
potential biomarkers in uterine aspirates. To do that, 
the uterine aspirates of two patients (one control and 
one EC patient) were split into four equal-volume 
aliquots and spiked with increasing volumes of 
full blood: 0, 10, 20, 40% (v/v). All samples were 
digested and analyzed by LC-MS/MS in duplicate. 
We excluded those proteins whose peptides displayed 
an increasing profile with an increasing concentration 
of spiked-in blood and maintained those proteins 
showing no effect or diminished levels (Figure 2). 
This criterion was used in order to discriminate protein 
biomarkers belonging to the endometrial tissue contained 
in uterine aspirates rather than proteins contained in 
the blood proteome. Moreover, by excluding abundant 
proteins of blood, we reduced analytical problems related 
to variable blood contamination among the samples. As 
a result of this analysis, 32 proteins were likely to be 
derived from the blood contamination of the uterine 
aspirates and were excluded from further analysis 
(Supplementary Figure 1).
The remaining 97 uterine aspirate specific 
candidates, and seven additional proteins detected in 
uterine aspirate samples but not in full blood (data not 
shown), were scaled down to 52 proteins based on their 
consistency in literature. The 52 candidates had undergone 
at least one level of additional validation using a different 
technology or biospecimen type, or an independent cohort 
of cases and controls whether in the context of the same 
publication or in an independent report. A total of two 
peptides per each of these 52 proteins (104 peptides) were 
selected according to their uniqueness, detection and 
chromatographic behavior. 
Figure 1: Experimental design. Stepwise workflow for the selection and prioritization of endometrial cancer biomarker candidates, and 
their verification in uterine aspirates by LC-PRM. DDA, data-dependent acquisition; PRM, parallel-reaction monitoring; EC, endometrial 
cancer; Adj p-value, adjusted p-value; AUC, Area under the ROC curve.
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Quality control of the LC-PRM data
The 52 proteins of interest were verified in the 
soluble fraction of uterine aspirates by targeted MS. Uterine 
aspirates from 20 EC patients and 18 non-EC controls 
were digested in duplicate and analyzed by a quadrupole-
orbitrap MS operated in PRM mode using a mix of the 
stable isotopes labeled (SIL) peptides of the 104 peptides 
(i.e., heavy peptides) as internal standards. Four of these 
SIL peptides could not be synthesized, leading to a final list 
of 100 monitored peptides in the method (Supplementary 
Table 2). The signals of the five most intense product ions 
for each precursor were extracted from the MS2 spectra to 
generate elution profiles (i.e. Extracted Ion Chromatograms 
(XICs) of selected product ions) (Supplementary Table 3). 
The identity of the peptides, as well as the potential 
interferences on the PRM traces, were evaluated by a 
similarity score based on the cosine of the spectral contrast 
angle (cos θ) calculated with the top five fragment ions of 
each precursor. This score was calculated against a reference 
LC-PRM analysis of the isotopically labeled peptides 
without biological matrix (Figure 3A). The signal of a 
peptide was accepted if the cos θ was higher than 0.98 for 
both the endogenous and the stable isotope labeled standard 
Figure 2: Effect of blood content on biomarker candidate detection. Experimental design and examples of concentration 
profiles of 3 potential biomarkers showing increasing and 3 decreasing profiles when uterine aspirate is diluted by increasing amount of full 
blood. The 32 candidates showing an increasing profile were rejected for further steps in the study. 
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[24]. Values lower than 0.98 due to an interfered PRM XIC 
were replaced by the next most intense available XIC of 
product ion. Six peptides were monitored by XICs of four 
product ions due to the absence of a clean fifth product ion 
(Supplementary Table 2). Following this, a positive spectral 
matching was achieved for 95.1% of a total of 7,350 pairs 
(ratio light/heavy). The unmatched 4.9% pairs were due 
to two conditions: i) measurements below the limits of 
detection (4.7%), which were replaced with an estimation 
of the background value. In this account, peptides below 
the limit of detection in more than 50% of the samples, 
only two peptides -VHITSLLPTPEDNLEIVLHR and 
VTILELFR- fulfilled this condition, were removed from the 
study; and ii) measurements for which less than four clean 
XICs of product ions were detected (0.2%). These 0.2% 
were due to data very close to, but below, cos θ = 0.98 and 
only one replicate was affected in all cases; thus the value 
of the accepted replicates was kept. These results illustrate 
the efficiency of the PRM acquisition in complex clinical 
samples. The use of internal standards and the availability of 
all XICs of product ions guarantee the correct identification 
of each peptide, reduce interferences and fasten the detection 
and exclusion of potential interferences in large datasets. 
The mean between duplicates in the cleansed dataset 
was calculated (Supplementary Table 4), as well as the 
correspondent coefficient of variation (CV%). The CV% of 
the duplicated sample preparation for each uterine aspirate 
sample was below 15% for 99% of the detected peptides, 
with an averaged CV of 3.6%. This confirmed the high 
reproducibility level of the full process (Figure 3B). Finally, 
the correlation between the peptides derived from the same 
protein was evaluated by a Pearson correlation coefficient 
(Figure 3C) and 39 out of the 46 (85%) proteins monitored 
with two peptides showed a very high correlation, with a R 
coefficient over 0.95. Only 3 proteins -ROA2, OSTP, and 
KPYM- presented an R coefficient below 0.9, which were 
due to the specificity of the monitored peptides to different 
isoforms of the same protein. 
Differentially abundant proteins between 
endometrial cancer and control uterine aspirates
In order to assess the potential of the 52 selected 
proteins to detect EC, we compared the abundance of 
each biomarker candidate between 20 EC patients and 18 
non-EC controls. Importantly, both patients and controls 
were postmenopausal women suffering from an abnormal 
vaginal bleeding, as these clinical features are present in 
93% of patients suffering from EC. However, only 15% of 
those will be finally diagnosed with EC [25]. 
Based on the Bradford assays, 250 ng of the total 
protein concentration after albumin and IgGs depletion 
was injected for each sample. The constant amount of 
injected protein among samples was further confirmed by 
the integration of the total ion chromatogram of the MS1 
scans, as shown in Supplementary Figure 2. After MS data 
curation, the relative levels (light/heavy ratios) of the final 
98 monitored peptides in MS2 were subjected to Mann 
Whitney test for their comparison between tumor and 
control samples. Forty eight peptides corresponding to 26 
proteins showed significant differences between the two 
groups with adjusted p-value < 0.05 (Benjamini corrected) 
and fold change greater than 3: PERM, CADH1, SPIT1, 
ENOA, MMP9, LDHA, CASP3, KPYM, PRDX1, OSTP, 
PDIA1, NAMPT, MIF, CTNB1, K2C8, ANXA2, CAPG, 
FABP5, MUC1, CAYP1, XPO2, NGAL, SG2A1, ANXA1, 
HSPB1, PIGR. All these proteins showed higher levels in 
tumor samples as compared to control samples (Table 1; 
Supplementary Figure 3). 
To further evaluate their performance as biomarkers 
for EC diagnosis, we performed a ROC analysis to 
determine the sensitivity and specificity of each biomarker. 
Interestingly, these differentially abundant proteins showed 
Area Under the ROC Curve (AUC) values for discriminating 
between EC and controls patients ranging from 0.75 to 
0.97. The 10 best-performing individual proteins were 
PERM, CADH1, SPIT1, ENOA, MMP9, LDHA, CASP3, 
KPYM isoform M1-M2, PRDX1 and OSTP isoform A, 
all of them with AUC values higher than 0.9 (Figure 4). 
Among those proteins, PERM, CADH1, SPIT1 and 
OSTP isoform A were of special interest as each of them 
presented sensitivities higher than 80% when specificity 
was fixed to 95% (Table 1). This is particularly important 
in EC diagnosis, as biomarkers with high specificity could 
complement the output of low invasive techniques such as 
the transvaginal ultrasonography, which currently presents 
very high sensitivity but lack of specificity [26]. 
Furthermore, we conducted a bioinformatics analysis 
using Ingenuity Pathway Analysis (IPA) to better understand 
the association of these proteins with cancer and their origin 
regarding the subcellular location. As expected, integration of 
the data resulted in the identification of cancer, inflammatory 
disease, organismal injury and abnormalities, and 
reproductive system disease as the top diseases associated 
to these biomarkers. The top five molecular and cellular 
functions involved with these proteins included cellular 
movement, cellular death and survival, cellular development, 
cellular growth and proliferation, and celltocell signaling and 
interaction, all of them important processes altered in cancer. 
These proteins are mainly found in the cytoplasm, plasma 
membrane and extracellular space (Table 1), indicating 
that they are coming either from secretion of the epithelial 
and inflammatory cells of the endometrium or by necrosis 
of cells in the proximal tissue. This is in concordance with 
the observation that all biomarkers in this study were found 
more abundant in EC patients as compared to controls, as 
both processes are related to the higher proliferation rate of 
epithelial cells in EC.
DISCUSSION 
About 30% of EC patients are diagnosed at 
advanced stages of the disease, associated with a drastic 
increase in the mortality and morbidity [1]. Therefore, 
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the identification of sensitive and specific biomarkers to 
improve early detection of EC is a crucial clinical need. 
Despite the major effort and investments made to identify 
EC biomarkers, no protein has yet reached the stage of 
clinical application. The poor translation of the results 
produced by those studies in the clinic can be explained 
by two determinant factors: on the one side, the lack of 
studies in biofluids to identify accessible EC biomarkers. 
Most of the studies were based in tissues, and/or those that 
used biofluids were limited to serum or plasma [27–29]. 
Blood presents several important advantages, as it is in 
direct contact with all body tissues, and its collection is 
rapid, easy and minimally invasive. However, the search 
of biomarkers in plasma or serum is extremely challenging 
due to the low concentration of the potential biomarkers 
and the wide dynamic range in protein abundance [30]. 
On the other side, the lack of verification studies as a 
bridge between discovery and validation phases, which 
Figure 3: Principle of PRM data quality control. (A) Peptide identity confirmation by comparison between PRM elution profiles of 
endogenous and internal standards of each biomarker candidate in the samples and a reference acquisition using the cosine of the spectral 
contrast angle (θ). A PRM measurement was accepted if the cos (θ) of both endogenous and internal standard are > 0.98. Values below 0.98 
due to interferences were solved by the substitution of the interfered XICs. Values below 0.98 due to the limit of detection were substituted 
by background. (B) Reproducibility of the analytical workflow. The sample preparation was duplicated and the coefficient of variation (CV) 
was below 15% for 99% of the detected peptides. (C) Pearson correlation between signatures peptides coming from the same protein. The 
score below 0.90 for three proteins is due to isoform specific peptides.
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Table 1: Proteins showing statistical differences between EC and control patients with adjusted 
p-value < 0.05 and fold change > 3
Uniprot 
Acces-
sion 
Number
Entrez 
Gene 
Name
Protein 
ID Peptide FC
Adjusted 
P-value
Tumor. 
Q1(25%)-
 Q3 
(75%)
Control. 
Q1(25%)- 
Q3( 75%)
AUC
Sensi-
tivity 
(%)
Speci-
ficity 
(%)
Sensitivity 
(%) when 
95% Spec-
ificity
Location
P05164
Myelo-
peroxi-
dase
PERM
IANVFTNAFR 14.1 6.E–05 0.56–2.18 0.04–0.13 0.97 95 89 80
Cytoplasm
VVLEGGIDPILR 13.3 1.E–04 0.94–4.00 0.08–0.29 0.95 95 89 70
P12830 E-cad-herin CADH1
VFYSIT-
GQGADTP-
PVGVFIIER
3.8 9.E–05 0.55–1.27 0.11–0.28 0.94 95 89 85 Plasma 
Membrane
NLVQIK 3.3 2.E–04 0.44–1.09 0.12–0.25 0.93 85 94 85
O43278
Kunitz-
type 
protease 
inhibi-
tor 1
SPIT1
SFVYGGCLGNK 3.3 1.E–04 0.33–0.66 0.07–0.20 0.93 95 94 95
Extracellu-
lar SpaceWYYDPTEQICK 3.3 1.E–04 0.30–0.55 0.06–0.18 0.93 90 94 90
P06733 Alpha-enolase ENOA
YISPDQLAD-
LYK 3.8 1.E–04 13.43–25.66 2.89–5.76 0.92 75 94 75 Cytoplasm
TIAPALVSK 4.0 2.E–04 6.85–18.62 1.51–3.23 0.89 80 83 70
P14780
Metal-
loprotein-
ase 9
MMP9
SLGPALLLLQK 5.7 1.E–04 0.52–2.42 0.05–0.19 0.91 95 83 60
Extracellu-
lar SpaceAFALWSAVT-
PLTFTR 5.5 1.E–04 0.35–1.60 0.03–0.14 0.91 90 83 60
P00338
Lactate 
dehydro-
genase A
LDHA
LVIITAGAR 6.2 1.E–04 3.55–7.23 0.26–0.78 0.91 85 89 65
Cytoplasm
VTLTSEEEAR 5.7 1.E–04 11.32–22.52 0.94–2.75 0.91 85 89 60
P42574 Cas-pase-3 CASP3
SGTDVDAAN-
LR 4.9 2.E–04 0.04–0.11 0.00–0.02 0.91 90 89 65 Cytoplasm
P14618 Pyruvate kinase
KPYM_
Isoform 
M1-M2
NTGIICTIGPASR 5.4 1.E–04 10.82–41.42 1.29–5.52 0.91 85 89 75
Cytoplasm
KPYM: 
Isoform 
M1-M3
APIIAVTR 3.1 1.E–02 0.43–1.39 0.10–0.51 0.75 60 89 50
Q06830 Peroxire-doxin-1 PRDX1
LVQAFQFTDK 4.2 2.E–04 11.08–27.24 2.06–7.32 0.90 75 94 75
Cytoplasm
ADEGISFR 4.2 2.E–04 0.80–1.93 0.16–0.52 0.90 75 94 75
P10451 Osteo-pontin
OSTP_
Isoform 
A
ANDESNEHSD-
VIDSQELSK 11.4 2.E–04 0.11–0.44 0.00–0.05 0.90 80 94 80
Extracellu-
lar SpaceOSTP_
Isoform 
A, B, D
AIPVAQDL-
NAPSDWDSR 9.0 4.E–04 0.10–0.56 0.01–0.07 0.87 80 83 50
P07237
Protein 
disulfide-
isomerase 
PDIA1
ILEFFGLK 3.3 3.E–04 0.16–0.41 0.03–0.13 0.89 75 89 65
Cytoplasm
ALAPEYAK 3.0 3.E–04 0.26–0.65 0.06–0.22 0.88 75 89 65
P43490 Visfatin NAMPT
YLLETSGN-
LDGLEYK 4.2 3.E–04 0.31–1.04 0.01–0.16 0.88 90 83 40 Extracellu-
lar Space
YDGHLPIEIK 4.0 3.E–04 0.57–2.05 0.08–0.32 0.88 90 83 40
P14174
Macro-
phage 
migration 
inhibitory 
factor 
MIF
VYINYYD-
MNAANVG-
WNNSTFA
4.2 3.E–04 0.91–1.89 0.05–0.45 0.88 75 94 75 Extracellu-
lar Space
LLCGLLAER 3.1 3.E–04 45.14–98.96 11.49–27.40 0.87 70 94 70
P35222 Beta-catenin CTNB1
LLNDEDQV-
VVNK 4.2 3.E–04 0.06–0.21 0.00–0.04 0.88 85 89 70 Nucleus
LVQLLVR 4.2 3.E–04 0.07–0.27 0.00–0.04 0.87 85 89 65
P05787
Keratin, 
type II 
cytoskel-
etal 8
K2C8
LSELEAALQR 3.6 3.E–04 1.04–2.99 0.17–0.92 0.88 95 67 65
Cytoplasm
WSLLQQQK 3.1 6.E–04 0.45–1.25 0.09–0.45 0.85 60 94 60
P07355 Annexin A2 ANXA2
GVDEV-
TIVNILTNR 4.8 4.E–04 5.60–20.24 1.36–4.74 0.87 75 89 45 Plasma 
Membrane
QDIAFAYQR 5.1 5.E–04 0.26–1.07 0.05–0.25 0.86 95 61 50
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has been defined as the current bottleneck of the biomarker 
pipeline [19, 21]. Discovery studies generate large lists of 
differentially abundant proteins. Many of those biomarker 
candidates are never validated or turn to be false positives 
due to the small number of samples analyzed, the biological 
variability or the limited quantitative performance of the 
technologies employed in this phase. There is a need to 
verify and refine those lists to the best candidates that can 
enter a validation phase. This is the critical role of the 
verification phase. In order to overcome these limitations, 
we presented a stepwise workflow to select potential 
EC biomarkers and verified them by targeted MS-based 
analysis in uterine aspirate samples.
Targeted MS-based approaches have gained in 
popularity for biomarker verification in complex clinical 
samples because they combine precision, sensitivity, 
multiplexing and absence of missing values. Among those, 
selected reaction monitoring (SRM) acquisition mode 
performed on a triple quadrupole mass spectrometer has 
been the reference method for the accurate quantification 
of peptides in biological matrices [31–33]. However, SRM 
is limited in selectivity and requires a substantial method 
development. We implemented the PRM acquisition, a new 
generation of targeted MS-based approach, performed on 
high-resolution accurate mass spectrometers (HRAM) such 
as the hybrid quadrupole-orbitrap. To date, the advantage of 
PRM for large scale analysis has been evaluated [24, 34] but 
not yet commonly introduced as a technique for biomarker 
searches in clinical [35] or cell lines samples [36–38]. The 
high resolution and the accurate mass (i.e. 35,000 at 200 
m/z and below 5 ppm) of the orbitrap analyzer decrease 
the risk of inferences due to the complexity of the chemical 
background and we obtained clear and easily readable 
chromatograms profiles. This aspect, in conjunction 
with the use of spectral matching as a quality metric, 
significantly facilitates the data processing to compare with 
SRM data, for instance only 0.2% of the chromatographic 
peak needed to be manually curated. A straightforward and 
highly automatable data processing is an important feature 
of large scale studies. The PRM acquisition allowed the 
quantification of 100 pairs of peptides at the reasonable 
throughput of one analysis per hour with an excellent 
precision (i.e. the CV% between full workflow duplicates 
was below 15% for 99% of the detected peptides). Finally, 
the design of an LC-PRM method is easier and faster 
than for LC-SRM, as the selection of the product ions to 
quantify is performed post-acquisition and the list of XICs 
can be refined iteratively to remove potential interferences 
coming from the background, without the need of a new 
analysis [39]. 
P40121
Macro-
phage-
capping 
protein
CAPG
EGNPEEDL-
TADK 3.6 5.E–04 0.32–1.11 0.05–0.17 0.85 85 83 45
Nucleus
YQEGGVES-
AFHK 3.5 6.E–04 0.44–1.63 0.08–0.27 0.85 80 83 45
Q01469
Fatty acid 
binding 
protein 5, 
epidermal
FABP5
LVVECVMN-
NVTCTR 3.9 6.E–04 2.27–8.29 0.84–1.56 0.85 90 78 45 Cytoplasm
ELGVGIALR 3.6 6.E–04 0.03–0.10 0.01–0.02 0.85 90 78 45
P15941 Mucin-1 MUC1 QGGFLGLSNIK 3.6 1.E–03 5.11–12.65 1.18–4.04 0.84 85 78 45 Plasma Membrane
Q13938 Calcy-phosine CAYP1
SGDGVVTVD-
DLR 3.4 1.E–03 4.04–19.35 1.16–3.48 0.83 85 78 45 Cytoplasm
P55060 Expor-tin-2 XPO2
AN-
IVHLMLSSPEQ-
IQK
4.0 1.E–03 0.05–0.19 0.00–0.04 0.83 75 89 25
Nucleus
LLQTDDEEEA-
GLLELLK 4.4 2.E–03 0.04–0.22 0.00–0.04 0.81 70 89 40
P80188 Lipo-calin2 NGAL
VPLQQNFQDN-
QFQGK 5.0 1.E–03 2.19–8.19 0.29–2.03 0.83 75 89 35 Extracellu-
lar Space
ELTSELK 4.4 4.E–03 2.09–9.13 0.35–2.04 0.79 70 83 30
O75556 Mamma-globin-B SG2A1
ELLQEFIDS-
DAAAEAMGK 3.3 3.E–03 0.15–0.35 0.02–0.17 0.80 90 72 30 Extracellu-
lar Space
TINSDISIPEYK 3.2 5.E–03 0.12–0.30 0.02–0.14 0.78 90 67 40
P04083 Annexin A1 ANXA1
DITSDTSGDFR 4.8 3.E–03 1.12–4.44 0.33–1.16 0.80 60 100 60
Plasma 
Membrane
GGPG-
SAVSPYPTF-
NPSSDVAALHK
3.9 7.E–03 1.33–6.02 0.51–2.02 0.77 55 100 55
P04792
Heat 
shock 
27kDa 
protein 1
HSPB1
LFDQAFGLPR 3.6 4.E–03 1.31–7.31 0.60–1.78 0.79 85 67 40
CytoplasmLATQSNE-
ITIPVTFESR 3.1 4.E–03 2.74–13.66 1.27–3.67 0.79 85 67 40
P01833
Poly-
meric 
immuno-
globulin 
receptor
PIGR VYTVDLGR 3.4 7.E–03 38.67–128.80 15.43–37.38 0.77 80 78 30 Plasma Membrane
FC, fold change; AUC, area under the curve; Q1, first quartile; Q3, third quartile.
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Another strength of this study is the use of uterine 
aspirates as a biological sample for biomarker detection. 
A useful diagnostic biomarker not only has to ameliorate 
the discrimination between patients suffering the disease 
and benign cases, but also should be economically 
profitable and advantageous in the clinical scenario. 
In the case of diagnostic biomarkers for EC, fasten the 
diagnostic process, improving the comfort of patients, 
and reducing the sanitary costs are very important values. 
Therefore, the search of biomarkers in easy-to-access 
biofluids is highly recommended. Uterine aspirates seem 
an interesting alternative to other biofluids, such as blood 
Figure 4: Scattering plots of the abundance of 17 peptides coming from 10 biomarkers in the verification study. 
Scattering plots depicting the distribution of the light/heavy (L/H) ratios across the 20 EC patients and 18 controls of the best individual 
performing peptides (AUC > 0.9) belonging to 10 biomarkers.
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or plasma, as they are in direct contact with the tumor 
in the endometrium, being enriched in proteins secreted 
from the epithelial cells in the tumor. Additionally, they 
are collected in the current process of EC diagnosis prior 
to subsequent more invasive diagnostic techniques. We 
here demonstrated the convenience of the soluble fraction 
of uterine aspirates as a source of EC biomarkers and the 
feasibility of its analysis by MS. The use of the soluble 
fraction is expected to overcome the diagnostic failure of 
22% associated to this sampling, as the current diagnostic 
procedure relies on the cellular material in the sample [4].
Our final achievement was to eliminate doubtful 
biomarker candidates derived from the variable amounts of 
blood contamination in uterine aspirates and successfully 
verify the differential abundance of 26 EC biomarkers 
in this sample. A bioinformatics analysis confirmed their 
individually and collectively association with cancer, 
and showed that they maintain a strong association with 
commonly altered molecular processes in cancer such 
as cellular movement, cellular death and survival, etc. 
Among all candidates, ten provided high sensitivity and 
specificity, with AUC values over 0.9, and four of those, 
PERM, CADH1, SPIT1 and OSTP, were highlighted as 
they achieved sensitivity over 80% when fixing a specificity 
of 95%. The protein biomarkers verified in this study merit 
further validation in an extended study with a larger cohort 
of patients and controls. A prospective large multicentric 
study has been initiated with the aim to confirm the 
diagnostic power of these biomarkers and hence, to 
evaluate their validity and clinical applications. A limitation 
of the present study is that we did not use combinations of 
multiple markers to avoid overfitting due to the relatively 
small number of subjects included [40]. However, the AUC 
for individual proteins were already very high.
In conclusion, this study brings forward the 
proteomic search of biomarkers in uterine aspirates 
following an appropriate workflow, and so, could be 
expanded to other types of gynecological diseases such 
as endometriosis and ovarian cancer. Moreover, this study 
proves the efficiency of high resolution MS in order to 
verify a large number of potential biomarkers to fill 
the gap between discovery and validation studies. The 
described workflow permitted to reduce step by step an 
initial list of 506 potential biomarkers down to 10 proteins 
with an increased likelihood to reach the stage of a clinical 
assay after a subsequent validation phase. 
MATERIALS AND METHODS
Reagents
Albumin and IgG Depletion SpinTrap columns 
were purchased from GE Healthcare (cat.no. 28-9480-
20). Sequencing grade modified trypsin was obtained 
from Promega (cat.no. V5111) and LysC endoproteinase 
MS grade was purchased from Thermo Scientific (cat.no. 
90051). Solid phase extraction cartridges, Sep Pak tC18, 50 
mg, were obtained from Waters (cat.no.WAT054960). SIL 
peptides were synthetized with a heavy C terminal lysine 
or arginine (C terminal arginine, 13C6, 15N4, Δm = 10 Da, 
C terminal lysine 13C6, 15N2, Δm = 8 Da) or when it was 
not applicable with a heavy leucine 13C6, 15N1, Δm = 7 Da 
or phenylalanine 13C9, 15N1, Δm = 10 Da. (Thermo Fisher, 
crude quality). The synthetic peptides were mixed together 
from the stock solutions (50% acetonitrile, 0.1% TFA), 
aliquoted in Eppendorf Low Bind tubes and stored at 80°C 
before single use. All other reagents were obtained from 
Sigma-Aldrich.
Patients and sample collection
A total of 42 patients (22 women suffering from 
EC and 20 non-EC controls, i.e., women having EC 
symptoms but not diagnosed with EC) were recruited in 
the Vall d’Hebron University Hospital (Barcelona, Spain) 
during 2012 to 2015. Informed consent forms, approved 
by the Vall d´Hebron Ethical Committee, were signed by 
all patients (approval number: PR_AMI_50-2012). The 
clinical and pathological characteristics of the patients are 
described in Supplementary Table 5. Inclusion criteria were 
postmenopause, a minimum age of 50 years and vaginal 
bleeding. Women who had been treated previously for 
gynecological pelvic cancer were excluded. Patients known 
to be positive for the human immunodeficiency virus and/or 
the hepatitis virus were excluded for safety reasons.
Uterine aspirates were collected by aspiration with 
a Cornier Pipelle (Eurogine Ref. 03040200) in the office 
of the clinician or in the operating room prior to surgery 
and transferred to 1.5 ml microtubes. Phosphate buffer 
saline was added in a 1:1 (v/v) ratio and centrifuged at 
2,500 rcf for 20 min in order to separate the soluble fraction 
(supernatant) from the solid fraction (pellet). The separated 
fractions were kept at −80°C until use. From the 42 
supernatants collected, samples coming from four patients 
were used for potential biomarker selection process and the 
development of the LC-PRM method. The list of selected 
biomarker candidates was then verified in the 20 EC and 18 
nonEC remaining samples by LCPRM analysis.
Evaluation of the detectability of potential 
protein biomarkers in uterine aspirates by  
LC-MS/MS analysis
Uterine aspirate supernatants from two patients 
diagnosed with EC and two non-EC controls were sonicated 
(Labsonic M, Sartorius Stedim Biotech) at 100% amplitude 
during 8 cycles of 15 seconds and 50 µl of each sample 
was depleted from albumin and IgG using the Albumin & 
IgG depletion spin trap kit according to the manufacturer’s 
instructions. Total protein concentration was measured 
by the Bradford assay, performed in triplicate. Proteins 
were purified by acetone precipitation overnight at −20ºC, 
resuspended with 0.2% Rapigest surfactant (Waters), 
sequentially digested at 37ºC by Lys-C (protease/total 
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protein amount ratio of 1/150 w/w) and trypsin (1/50 w/w) 
overnight, and finally desalted onto SPE cartridges. The 
LC-MS detectability of 506 potential biomarkers in the 
supernatants of uterine aspirate samples was then evaluated 
using a LTQ-Orbitrap Velos mass spectrometer (Thermo 
Scientific) operated in data dependent acquisition (DDA) 
mode. The liquid chromatography system consisted of an 
UltiMate 3000 RSLC nano configured in binary gradient 
mode. The setup was operated in column switching mode 
and samples were loaded onto a trap column (Acclaim 
PepMap100 2 cm × 75 μm i.d., C18, 3 μm, 100 Å) for 
3 min at 5 µl/min by an aqueous solution containing 0.05% 
trifluoroacetic acid and 1% acetonitrile (v/v). Peptides 
were then eluted onto an analytical column (Acclaim 
PepMap RSLC 15 cm × 75 μm i.d., C18, 2 μm, 100 Å) 
by applying a 66 min linear gradient from 2 to 35% 
solvent B at 300 nl/min. The solvents A and B consisted 
of water with 0.1% (v/v) formic acid and acetonitrile with 
0.1% (v/v) formic acid, respectively. The electrospray 
ionization was performed through a fused silica emitter 
by applying a voltage of 1.5 kV. The DDA method was 
based on a high resolution survey scan (60,000 at 400 m/z) 
followed by the fragmentation and analysis of the 6 most 
intense precursor ions in the LTQ ion trap at normalized 
collision energy of 35. Dynamic exclusion of precursors 
already selected for MS/MS experiments was set to 90 s. 
Peptides and related proteins identification was performed 
using Proteome Discoverer software (v1.4) (Thermo 
Scientific, Waltham, MA, USA) by Mascot search engine 
using Swiss-Prot human database (SwissProt 201108 with 
531473 sequences entries, restricted to the 20,245 entries 
of the human taxonomy). Trypsin specificity was set to 
cleave after arginine and lysine residues excepted when 
flanked by a proline on the C-terminal side. A fragment ion 
mass tolerance of 0.8 Da and a precursor mass tolerance of 
10 ppm were applied. Up to one tryptic missed cleavage 
was tolerated and carbamidomethylation of cystein 
and oxidation of methionine were specified as dynamic 
modifications. Results were filtered by Proteome Discoverer 
using one peptide per protein, a maximum search engine 
rank of 1 and a false discovery rate (FDR) below 0.01 
(calculated by the node “Target decoy PSM validator”). The 
expectation value for accepting a spectrum was below 4 * 
10−3 to set FDR at 0.01. 
Effect of differential blood content on biomarker 
candidate detection in uterine aspirates
Uterine aspirates from one EC and one control 
patients were split into four equal-volume aliquots and 
spiked with increasing volumes of full blood (0, 10, 20 and 
40% (v/v)). Samples were centrifuged at 2500 rcf for 20 
min in order to separate the soluble part from the pellet. 
Supernatants were treated and analyzed by LC-MS/MS as 
described in the previous paragraph. The elution profile 
areas of peptides of 129 potential biomarkers identified in 
the uterine aspirates of these two patients with the different 
percentage of blood added and/or full blood were extracted 
from the high resolution survey scans (the identity of 
peptide was confirmed by MS2) using Skyline software 
(v3.1) (McCoss Lab, University of Washington, Seattle, 
WA, USA). The levels of the surrogate peptides of each 
protein across the four aliquots with increasing percentage 
of full blood were plotted. The slope of the linear regression 
was calculated for each peptide and those presenting a 
positive slope in both patients were rejected from the study.
Preparation of uterine aspirate samples for the 
LC-PRM analysis
Supernatants from uterine aspirates coming from 
20 EC patients and 18 non-EC controls were sonicated to 
disrupt potential microvesicles, protein aggregates, and/
or mucus by 5 cycles at 100% amplitude during 5 seconds 
(Labsonic M, Sartorius Stedim Biotech). Albumin and 
immunoglobulin G were then depleted from 50 µl of 
supernatant samples using the Albumin & IgG depletion 
spin trap kit according to the manufacturer’s instructions. 
Total protein concentration was measured by the Bradford 
assay performed in triplicate. Each of the 38 samples 
were then separated into two aliquots of 25 µg to generate 
duplicates for the whole process, with exception of one 
sample for which the amount of material was not sufficient 
for duplication. The samples were diluted into a 50 mM 
solution of ammonium bicarbonate to a final volume of 
120 µl and were denatured by addition of 185 µl of 10 
M urea suspended in 50 mM ammonium bicarbonate, 
incubated at 22°C under agitation for 20 min, and followed 
by 10 min incubation in an ultrasonic bath (Branson 5510, 
Branson Ultrasonics). The samples were then reduced 
with 7.8 µl of 200 mM dithiothreitol for 60 min at 37°C, 
and alkylated with 12.2 µl of 400 mM iodoacetamide at 
22°C for 30 min in the dark. The samples were digested 
for 4 h at 37°C with LysC (protease/total protein amount 
ratio of 1/150; w/w). Afterwards, the concentration of urea 
was diluted to 1 M with 50 mM ammonium bicarbonate 
buffer, and samples were incubated overnight at 37°C with 
trypsin (protease/total protein amount ratio of 1/50; w/w). 
The trypsin activity was quenched by addition of 1 µl of 
neat formic acid per 100 µl of solution. The samples were 
spiked with the mix of heavy synthetic peptides and then 
desalted onto solid phase extraction cartridges. The eluates 
were subsequently evaporated to dryness in a vacuum 
centrifuge and suspended in 0.1% formic acid before LC-
PRM analysis.
LC-PRM setup 
The LCMS setup consisted of a Dionex Ultimate 
3000 RSLC chromatography system configured for a 
high-pressure binary gradient and operated in column 
switching mode. The mobile phase A consisted of 0.1% 
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formic acid in water, the phase B in 0.1% formic acid in 
acetonitrile and the loading phase in 0.05% trifluoroacetic 
acid and 1% acetonitrile in water. The equivalent of 250 
ng of each digested sample was injected and loaded onto 
a trap column (75 µm × 2 cm, C18 pepmap 100, 3 µm) at 
5 µl/min and further eluted onto the analytical column 
(75 µm × 15 cm, C18 pepmap 100, 2µm) at 300 nl/min by a 
linear gradient starting from 2 % A to 35 % B in 48 min. The 
MS analysis was performed by a hybrid quadrupole orbitrap 
mass spectrometer (Q Exactive plus, Thermo Scientific) 
operated in PRM mode. The MS cycle started with a full 
MS1 scan performed at a resolving power of 70,000 (at 
200 m/z) followed by time scheduled targeted PRM scans 
acquired at a resolving power of 35,000  (at 200 m/z) 
with a normalized collision energy of 20. The quadrupole 
isolation window for the PRM events was set to 1 m/z unit 
and the duration of the time scheduled windows for each 
pair of endogenous and isotopically labeled peptides were 
set to 2 min. PRM data are accessible in a public database 
(Panorama server) at: https://panoramaweb.org/labkey/
PRM_analysis_of_EC_uterine_aspirate.url; reviewer 
account is: panorama+domon@proteinms.net; Password is: 
KTjy3~A#.
PRM data processing 
The elution profile of the five most intense fragment 
ions of each precursor were extracted using Skyline. The 
selection of the best product ions was supported by a spectral 
library obtained from a reference LC-PRM acquisition of the 
synthetic peptide mix injected without biological matrix. The 
elution profiles of the samples were first manually reviewed 
and obvious interfered PRM XICs were replaced by the 
next most intense available product ion. The data set was 
then refined using the cosine of the spectral contrast angle 
(cos θ) calculated between the peak areas of the five  XICs 
of product ions of the reference  (PRM acquisition of the 
synthetic peptides mix) and the areas of the corresponding 
XICs for the endogenous and heavy peptides in the 
biological samples [41]. The formula is as follows:
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Where Aexp are the areas of either the endogenous 
or heavy XICs of selected product ions for a peptide 
measured in a sample, and Aref are the areas of the same 
XICs measured in a reference synthetic peptides mixture. 
Peptides detection and identification were confirmed 
if the cos θ of the endogenous and the isotope labeled 
peptide were higher than 0.98 [24]. Scores below 0.98 are 
principally due to MS measurements below the limit of 
detection and in such cases the area values were replaced 
by an estimation of the background. Peptides with cos 
θ below 0.98 in more than 50% of the 38 samples in 
duplicates were eliminated from the verification study. 
For the quantitative analysis, the area ratios between 
the endogenous and their corresponding heavy peptides 
were compared between samples. The area ratios were 
calculated as the sum of the areas of the XICs of products 
ions of the endogenous peptide divided by the sum of the 
XICs of the respective isotope labeled version.  
Statistical analysis
The statistical analysis was performed in SPSS 
(v20.0) (IBM, Armonk, NY, USA) and Graph Pad Prism 
(v.6.0) (GraphPad Software, La Jolla, CA, USA). The 
averaged light/heavy area ratios were calculated between 
duplicates. The linear correlation between the signature 
peptides of the same protein was calculated using the 
Pearson correlation coefficient. Due to the non-normality of 
the data, assessed by Kolmogorov-Smirnova and Shapiro-
Wilk tests, comparison of the abundance of the monitored 
peptides between tumor and control samples was performed 
using the non-parametric Mann-Whitney U test. P-values 
were adjusted for multiple comparisons using Benjamini-
Hochberg FDR method [42]. Adjusted p-values lower 
than 0.05 along with fold changes greater than three were 
considered statistically significant. Receiver operating 
characteristic (ROC) curves were used to calculate the 
relationship between sensitivity and specificity for EC 
versus non-EC control group and hence, to evaluate the 
diagnostic performance for each biomarker candidate.
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